Interaction of terbinafine (anti-fungal agent) with perhexiline: A case report

Heart Lung and Circulation

Volumn 23, Issue 6, 2014, Pages

  Sheikh, Abdul Rauf ^a,b   Westley, Ian ^b,d   Sallustio, Benedetta ^b,c   Horowitz, John D ^a,b   Beltrame, John F ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Cytochrome P450 2D6 (CYP2D6); Perhexiline; Selective serotonin re uptake inhibitors (ssris); Terbinafine

Indexed keywords

PERHEXILINE; TERBINAFINE; ANTIFUNGAL AGENT; CALCIUM CHANNEL BLOCKING AGENT; NAPHTHALENE DERIVATIVE;

ADULT; ANGINA PECTORIS; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EXERCISE TOLERANCE; HUMAN; MALE; MIDDLE AGED; NAUSEA; PRIORITY JOURNAL; TOENAIL ONYCHOMYCOSIS; DRUG INTERACTION;

ANTIFUNGAL AGENTS; CALCIUM CHANNEL BLOCKERS; DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; PERHEXILINE;

EID: 84904541790     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2013.11.012     Document Type: Article

References (18)

1. Brown MJ, Horowitz JD, Mashford ML. A double blind trial of perhexiline maleate in the prophylaxis of angina pectoris. Med J Aust 1976;1 (9):260-3.
2. Unger SA, Robinson MA, Horowitz JD. Perhexiline improves symptomatic status in elderly patients with severe aortic stenosis. Aust N Z J Med 1997;27(1):24-8.
3. Phan TT, Shivu GN, Choudhury A, Abozguia K, Davies C, Naidoo U, et al. Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina: old drug, new hope. Eur J Heart Fail 2009;11(9):881-6.
4. Sheila M, Killalea, Henry Krum. Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease. Am J Cardiovasc Drugs 2001;1(3):193-204.
5. Horowitz JD, Sia ST, MacDonald PS, Goble AJ, Louis WJ. Perhexiline maleate treatment for severe angina pectoris correlation with phannacokinetics. Int J Cardiol 1986;13:219-29.
6. Cole PL, Beamer AD, McGowan N, Cantillon CO, Benfell K, Kelly RA, et al. Efficacy and safety of perhexiline maleate in refractory angina. Circulation 1990;81(4):1260-70.
7. Alderman CP, Hundertmark JD, Soetratma TW. Interaction of serotonin re-uptake inhibitors with perhexiline. Aust N Z J Psychiatry 1997;31:601-3.
8. Alderman CP. Perhexiline-paroxetine drug interaction. Australian Journal of Hospital Pharmacy Aug 1998;Vol. 28(No. 4):254-5.
9. Young-Min Park. Prolonged Drug-Drug Interaction between Terbinafine and Perphenazine. Psychiatry Investig Dec 2012;9(4):422-4.
10. Castberg I, Helle J, Aamo TO. Prolonged pharmacokinetic drug interaction between terbinafine and amitriptyline. Ther Drug Monit 2005;27:680-2.
11. Davies BJ, Coller JK, James HM, Gillis D, Somogyi AA, Horowitz JD, et al. Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline. Br J Clin Pharmacol Apr 2004;57(4):456-63.
12. Castberg I, Helle J, Aamo TO. Prolonged pharmacokinetic drug interaction between terbinafine and amitriptyline. Ther Drug Monit 2005;27:680-2.
13. Faergemann J, Zehender H, Denouël J, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day or four weeks. Acta Derm Venereol 1993;73:305-9.
14. Zehender F, Cabiac MD, Denouël J, Faergemann J, Donatsch P, Kutz K, et al. Elimination kinetics of terbinafine from human plasma and tissues following multiple dose administration and comparison with 3 main metabolites. Drug Invest 1994;8:203-10.
15. Kovarik JM, Mueller EA, Zehender H, Denouël J, Caplain H, Millerioux L. Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites Antimicrob Agents Chemother 1995;39:2738-40.
16. Flockhart DA. Drug Interactions Cytochrome P450 Drug Interaction Table Indiana University School of Medicine; 2007.
17. Zhang W, Ramamoorthy Y, Tyndale RF, Sellers EM. Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos June 2003;31(6):768-72.
18. Nyfort-Hansen K. Perhexiline toxicity related to citalopram use. Med J Aus 2002;176(11):560-1.